Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS ...
Biotech stocks took a hit after President Trump’s tariff comments spooked investors harder than a surprise lab result. Amgen led the sector’s dip with a 2.39% drop, while Regeneron and Merck also slid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback